NCT01498900View on ClinicalTrials.gov

An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice

CompletedOBSERVATIONAL

Enrollment

30,554

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

repaglinide

Prescription according to the product labelling at the physicians' discretion

Trial Locations (1)

34335

Novo Nordisk Investigational Site, Istanbul

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY